Iovance Biotherapeutics Inc（IOVA）股票分析IOVAIovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Iovance Biotherapeutics Inc is a good buy right now due to its recent revenue guidance increase to $410-$420 million, reflecting nearly 60% growth from last year, and a current price of $14.62, which is below several analyst price targets, including $20 from H.C. Wainwright. The RSI is at 73.111, indicating strong momentum, although it is approaching overbought territory. The main risk is the negative net income of -47.36% in the latest quarter, which could impact future performance.

7 analysts cover IOVA: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.50.